Domperidone in the Treatment of Dyspepsia: A Double-Blind Placebo-Controlled Study

Abstract

Domperidone, at a dosage of 20 mg t.d.s. before meals, in a double-blind, crossover, placebo-controlled trial reduced the level of the symptoms of dyspepsia by 76% compared to a 16% reduction with placebo. This difference was statistically significant (p <0·001). Thirteen of the fourteen patients in the study preferred domperidone to placebo. Four patients in the active treatment period and one in the placebo complained of mild side-effects.